[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 248,005
  • Shares Outstanding, K 268,258
  • Annual Sales, $ 236,200 K
  • Annual Income, $ -5,350 K
  • EBIT $ 5 M
  • EBITDA $ 7 M
  • 60-Month Beta 0.26
  • Price/Sales 1.02
  • Price/Cash Flow N/A
  • Price/Book 8.81
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.03 on 05/07/26
  • Next Earnings Date 08/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 183.13% (-130.12%)
  • Historical Volatility 94.80%
  • IV Percentile 76%
  • IV Rank 33.01%
  • IV High 442.51% on 02/19/26
  • IV Low 55.31% on 05/18/26
  • Expected Move (DTE 3) 0.0510 (5.52%)
  • Put/Call Vol Ratio 3.12
  • Today's Volume 136
  • Volume Avg (30-Day) 366
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 31,525
  • Open Int (30-Day) 29,878
  • Expected Range 0.8735 to 0.9755

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 2
  • High Estimate $-0.02
  • Low Estimate $-0.03
  • Prior Year $0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8227 +12.37%
on 06/10/26
1.2000 -22.96%
on 05/13/26
-0.2555 (-21.65%)
since 05/12/26
3-Month
0.8227 +12.37%
on 06/10/26
1.5950 -42.04%
on 04/15/26
-0.4755 (-33.96%)
since 03/12/26
52-Week
0.8227 +12.37%
on 06/10/26
4.0787 -77.33%
on 07/11/25
-2.7255 (-74.67%)
since 06/12/25

Most Recent Stories

More News
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics: Q1 Earnings Snapshot

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Q1 2026 Vafseo® (vadadustat) net product revenues grew to  $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial...

AKBA : 0.9245 (+2.79%)
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 0.9245 (+2.79%)

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.0364
2nd Resistance Point 0.9978
1st Resistance Point 0.9611
Last Price 0.9245
1st Support Level 0.8858
2nd Support Level 0.8472
3rd Support Level 0.8105

See More

52-Week High 4.0787
Fibonacci 61.8% 2.8349
Fibonacci 50% 2.4507
Fibonacci 38.2% 2.0665
Last Price 0.9245
52-Week Low 0.8227

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.